4D Molecular Therapeutics (FDMT) Interest Expenses (2019 - 2026)
4D Molecular Therapeutics (FDMT) posted quarterly Interest Expenses of $26.2 million for Q1 2026, up 1768.21% year-over-year from $1.4 million in Q1 2025, and up 1768.21% quarter-over-quarter from $1.4 million in Q4 2025.
4D Molecular Therapeutics (FDMT) Interest Expenses (2019 - 2026) Analysis & Trends
4D Molecular Therapeutics (FDMT) has reported Interest Expenses for 8 consecutive years, with $26.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Interest Expenses rose 1768.21% year-over-year to $26.2 million; the TTM figure through Mar 2026 stood at $26.2 million (up 570.64% YoY), while the FY2025 annual figure was $158.6 million, up 23.79% from the prior year.
- Interest Expenses advanced to $26.2 million in Q1 2026 per FDMT's latest filing, from $1.4 million in the prior quarter.
- Across five years, Interest Expenses topped out at $34.1 million in Q3 2024 and bottomed at $800000.0 in Q4 2023.
- Historically, Interest Expenses has averaged $13.1 million across 5 years, with a median of $5.7 million in 2022.
- Annual changes were most pronounced in 2024 — Interest Expenses plunged 96.02% — and 2026, when it jumped 1768.21%.
- 4D Molecular Therapeutics' Interest Expenses stood at $2.9 million in 2022, then slumped by 72.41% to $800000.0 in 2023, then increased by 12.5% to $900000.0 in 2024, then surged by 55.56% to $1.4 million in 2025, then surged by 1768.21% to $26.2 million in 2026.
- Business Quant data shows FDMT's Interest Expenses at $26.2 million in Q1 2026, $1.4 million in Q4 2025, and $29.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | 4D Molecular Therapeutics | 856.62 Mn | 495.28 Mn | - | 24.72 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 24.72 Mn |
| Jun 30, 2026 | 24.72 Mn |
| Mar 31, 2026 | 26.16 Mn |
| Mar 31, 2026 | 26.16 Mn |
| Dec 31, 2025 | 1.40 Mn |
| Dec 31, 2025 | 1.40 Mn |
| Sep 30, 2025 | 29.02 Mn |
| Sep 30, 2025 | 29.02 Mn |
| Jun 30, 2025 | 30.44 Mn |
| Jun 30, 2025 | 30.44 Mn |
| Mar 31, 2025 | 1.40 Mn |
| Mar 31, 2025 | 1.40 Mn |
| Dec 31, 2024 | 900,000.00 |
| Dec 31, 2024 | 900,000.00 |
| Sep 30, 2024 | 34.11 Mn |
| Sep 30, 2024 | 34.11 Mn |
| Jun 30, 2024 | 2.81 Mn |
| Jun 30, 2024 | 2.81 Mn |
| Mar 31, 2024 | 800,000.00 |
| Mar 31, 2024 | 800,000.00 |